Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin with DHAP in Relapsed/Refractory Hodgkin Lymphoma
NCT02280993Phase 1Unknown
- Start
- May 2014
- Primary completion
- Nov 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of brentuximab vedotin in Hodgkin lymphoma (HL). Primary endpoint: Rate of patient with grade 4 Adverse Events at 12 weeks. Status: unknown.
02
Drugs
brentuximab vedotin
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT02280993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02280993.